Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
News|Articles|December 3, 2024
Endoscopy in the Age of GLP-1 RAs: 2024 Sees New Risk-Based Perioperative Guidance
Author(s)Abigail Brooks, MA
Previous ASA guidance recommended holding GLP-1 RAs in the perioperative period, but new 2024 multisociety guidance suggests a risk-based approach.
Advertisement
Advertisement
The recent rise of GLP-1 receptor agonists (GLP-1 RAs) has been nothing short of revolutionary for the field of medicine, with no other class of medications matching their profound impact across multiple disciplines.
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.
HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.
With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.
Advertisement
Advertisement